Molecular Alterations in Thyroid Carcinoma.

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Thyroid carcinoma is the most prevalent endocrine system malignancy.
• Next-generation sequencing has advanced understanding of thyroid cancer's molecular basis.
• Constitutive activation of the mitogen-activated protein kinase (MAPK) pathway is crucial in thyroid tumorigenesis.

Purpose of the Study:

• To provide a concise and updated summary of the primary genetic alterations in thyroid carcinoma.
• To highlight the role of specific mutations and fusions in thyroid cancer development.
• To discuss the implications of these molecular findings for targeted therapies.

Main Methods:

• Review of recent advances in next-generation sequencing.
• Analysis of molecular pathogenesis of thyroid cancer.
• Identification of key genetic alterations and molecular signatures.

Main Results:

• RAS mutations, BRAF mutations, and RET-PTC fusions are central to MAPK pathway activation and tumorigenesis.
• TERT promoter and TP53 mutations are linked to tumor progression.
• These genetic alterations offer potential targets for tyrosine kinase inhibitor therapy.

Conclusions:

• Understanding the genetic landscape of thyroid carcinoma is critical for diagnosis and treatment.
• Targeting activated molecular pathways presents a promising therapeutic strategy.
• Continued research into molecular signatures will refine prognostication and treatment selection.